The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. - Wikidata - thesis-toulmin - TriplyDB

The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans.

The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans.

http://www.wikidata.org/entity/Q37451440

about

The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement.Preliminary Study of Plasma Exosomal Tau as a Potential Biomarker for Chronic Traumatic Encephalopathy.Repetitive head impact exposure and later-life plasma total tau in former National Football League players.Effects of traumatic brain injury and posttraumatic stress disorder on development of Alzheimer's disease in Vietnam Veterans using the Alzheimer's Disease Neuroimaging Initiative: Preliminary Report.Multiple system atrophy: pathogenic mechanisms and biomarkers.The Role of Cerebrospinal Fluid Biomarkers in the Evolution of Diagnostic Criteria in Alzheimer's Disease: Shortcomings in Prodromal Diagnosis.Metabolic network failures in Alzheimer's disease: A biochemical road map.CSF protein changes associated with hippocampal sclerosis risk gene variants highlight impact of GRN/PGRN.Amyloid Beta and Tau as Alzheimer's Disease Blood Biomarkers: Promise From New Technologies.Plasma Levels of Aβ42 and Tau Identified Probable Alzheimer's Dementia: Findings in Two Cohorts.Neuropathological assessment and validation of mouse models for Alzheimer's disease: applying NIA-AA guidelines.Mapping longitudinal scientific progress, collaboration and impact of the Alzheimer's disease neuroimaging initiative.Tau-mediated Neurodegeneration and Potential Implications in Diagnosis and Treatment of Alzheimer's Disease.Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.Alzheimer disease brain atrophy subtypes are associated with cognition and rate of decline.Potential clinical utility of multiple system atrophy biomarkers.Performance Evaluation of an Automated ELISA System for Alzheimer's Disease Detection in Clinical Routine.A Longitudinal Study of Total and Phosphorylated α-Synuclein with Other Biomarkers in Cerebrospinal Fluid of Alzheimer's Disease and Mild Cognitive Impairment.

P2860

Q31147579-857770AA-4A40-480F-B168-CFB8CAAD8806 Q36803316-3CE88DB8-42AB-45A0-BE28-1664C6CE78CC Q37645272-1989A4B8-CA65-45E2-9EDD-D353FBD97003 Q38649532-BF8FD020-5540-48F5-919A-EAA31982B486 Q38813304-2D79C639-DAB1-4B4B-A687-7844B10EDA0C Q38830945-9A52B6F2-0F1D-4031-9D25-FB732AED09C3 Q38877855-037DCFA9-2F6F-4C26-879E-4A8CE2BFF06C Q38965615-FF0BF9E4-63F0-450E-9AC2-18535831473F Q39451611-D1B64936-1327-4D66-894F-C68BD6383E40 Q41097447-1A69785F-FA44-4DED-9B1C-ED9D76ECFD2C Q42643490-1B0CEE26-2F77-40AD-A032-E5C71406E94F Q45077670-6BE89F26-FA79-46A9-B598-C85F198500AF Q47296152-7D845374-24FB-4376-A506-360B2755C312 Q47587631-977D89C1-CACA-443C-B47E-6B1447FA92D9 Q47588927-AF9668BE-A38E-4378-9AAA-E27B78A66CD8 Q47663712-8E2BC0AF-6990-4409-8C6D-8E074A193C02 Q47976273-93169530-38BA-4A1F-9950-C87EB842A4B6 Q49613405-EE4D0476-FB76-477D-8D10-D0A013148B43

P2860

The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans.

http://www.wikidata.org/entity/Q37451440

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

The Alzheimer's Disease Neuroi ...... review of progress and plans.

@en

The Alzheimer's Disease Neuroi ...... review of progress and plans.

@nl

type

label

The Alzheimer's Disease Neuroi ...... review of progress and plans.

@en

The Alzheimer's Disease Neuroi ...... review of progress and plans.

@nl

prefLabel

The Alzheimer's Disease Neuroi ...... review of progress and plans.

@en

The Alzheimer's Disease Neuroi ...... review of progress and plans.

@nl

P1433

Q37451440-E12F1E14-4BFE-4BFA-B5BA-430D38C58F8E

P1476

Q37451440-9FD34EE2-ADB7-4B31-9A3E-8ADC91A5EFE7

P2093

Q37451440-0EDFC215-E81F-45EC-B689-1A5903AC4DA2

Q37451440-3F1903DA-19D7-4BAC-99D6-57BA639C7035

Q37451440-4F1B0645-415A-4BD9-90C4-A136F6DB0B16

Q37451440-674273E0-A7A2-4509-A720-B9CFFCB40F97

Q37451440-6B590757-E5E0-45D4-A4EB-CBF4996B0055

Q37451440-B3D1F317-B03F-4CE2-A2FE-102440333C5E

Q37451440-BA33020C-EA8B-404A-A949-B0900DFE0568

Q37451440-DC7E652C-F459-4549-B96F-60127C4185A1

Q37451440-E46E9036-DFAD-4AB3-B06C-3250343E0AAD

Q37451440-FF445415-4129-4531-B3DC-E18D5770618D

P2860

Q37451440-0598497C-0B63-4D73-8C44-D55AAEA6BA5D

Q37451440-07630020-1535-4AF6-8F59-A544E0ADD00B

Q37451440-084679E4-3866-433B-9346-02528A0253F8

Q37451440-08D69A1A-00FA-44E8-88D5-2A256945BE53

Q37451440-09B94385-BFDF-420C-9185-3678E4B4B40B

Q37451440-0A367CE3-7B85-491A-A65F-01F025AF5610

Q37451440-0B618BE3-E2E5-4CEA-8EAC-10EC03007A83

Q37451440-0D359534-A284-4B9F-A2A2-429A66B5AAEF

Q37451440-0DBA4DF3-CF75-4229-8E00-93DA7DB28F7E

Q37451440-0E22B93D-C8A6-4EDD-8C58-952D554AF37C

P304

Q37451440-02EBD495-47B9-4CD2-9D1B-2B97EA71BC30

P31

Q37451440-85942B8F-AFD0-4883-A3FE-8F37243FF5CE

P356

Q37451440-69B9FCE0-0F89-4479-AAEB-C70D1E5D0769

P407

Q37451440-936E5D1D-41D8-46E5-B057-A95BA41160A2

P433

Q37451440-CE40E9AB-C9A9-49DC-AF84-7A68F668DF69

P478

Q37451440-EC52190E-86E6-4562-9EAC-3B0B45F458C6

P50

Q37451440-02E3E9DA-FDEC-43A6-AC10-53021B5E5883

Q37451440-0D0213FA-D383-48FC-946E-79D9DDB833F9

Q37451440-30BDC835-FB24-46A6-94B5-C29F5EC40DBA

Q37451440-391B4F09-6035-45A3-8089-9AC39C73F326

Q37451440-3D07546E-E6B8-49DB-8888-68080BA4C77C

Q37451440-625592DC-1CB2-41B4-B733-A152E03B97A6

Q37451440-86286B11-535F-4F60-BF7C-93091B4EF387

Q37451440-BD9B302B-BF1C-40D0-AE3E-E53838E9F05B

Q37451440-CC8BF7A4-003B-4885-9DEF-D6708CC42363

Q37451440-DE8C6977-8881-47B7-81AB-E27D5CD2D8DD

P577

Q37451440-C3F901C5-5745-4DC4-9D47-483B6F657759

P5875

Q37451440-46C7EF83-F2B0-4528-9859-A6D7AA1E61D5

P698

Q37451440-047E05D7-0BB3-492B-8AD3-0AFCE511A645

P921

Q37451440-25C840A8-EBE9-425A-A3C3-5D7A4A26B796

Q37451440-6A058467-25AE-4847-955C-E0B470AE07AF

Q37451440-D135A446-B48D-44CD-95CF-22CF419ED021

Q37451440-DAC6142B-795C-48F6-9C3C-69B67C32172F

P932

Q37451440-E660C39F-2D38-4615-A501-160D3C6E4F5B

P356

J.JALZ.2015.05.003

P1433

Alzheimer's and Dementia

P1476

The Alzheimer's Disease Neuroi ...... review of progress and plans.

@en

P2093

Holly Soares

http://www.w3.org/2001/XMLSchema#string

Hugo Vanderstichele

http://www.w3.org/2001/XMLSchema#string

Ju-Hee Kang

http://www.w3.org/2001/XMLSchema#string

Leona Fields

http://www.w3.org/2001/XMLSchema#string

Leslie M Shaw

http://www.w3.org/2001/XMLSchema#string

Magdalena Brylska

http://www.w3.org/2001/XMLSchema#string

Michal J Figurski

http://www.w3.org/2001/XMLSchema#string

Nirali Shah

http://www.w3.org/2001/XMLSchema#string

Robert A Dean

http://www.w3.org/2001/XMLSchema#string

Teresa Waligorska

http://www.w3.org/2001/XMLSchema#string

P2860

Role of Genes and Environments for Explaining Alzheimer Disease

Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people

Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease

Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients

The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception

Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkers

Tau imaging: early progress and future directions

Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis

P304

772-791

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JALZ.2015.05.003

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Andrew J. Saykin

Alzheimer's Disease Neuroimaging Initiative

Ronald C. Petersen

Michael W. Weiner

Magdalena Korecka

Henrik Zetterberg

John Q. Trojanowski

P577

2015-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

280241902

http://www.w3.org/2001/XMLSchema#string

P698

26194312

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

Alzheimer's Disease Neuroimaging Initiative

P932

5127404

http://www.w3.org/2001/XMLSchema#string